Skip to main content

Table 1 All carriers combined high cumulative release with intact antimicrobial activity, only the cements had residual GS after release. The total release is also given as percentage of the 30 mg/g that was added during production. (a)Total release from three high release cements (Biofil, Bonesource and Chronos) was significantly higher than from low release cements Biobon and Norian and than low release granules Bonesave and Biosorb. (b)The release from Chronos was also higher than from low release cement Calcibon (all p < 0.05). Only two cements showed continuous release (Biobon and Bonesource for 17 days). For comparison, available gentamicin extracted from samples ground immediately after production is shown in the control column. Values are means ± SD of at least three experiments in triplicate.

From: In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile

Carrier Gentamicin (mg/g) Killing
  cumulative release (%) residual control (%)
Cements
Biobon 14.0 ± 3.6 46.7 2.1 ± 2.1 17.1 ± 0.0 99.8
Biofil 23.2 ± 4.0 77.3a 0.9 ± 0.3 21.3 ± 3.9 99.7
Bonesource 25.3 ± 2.5 84.3a 1.8 ± 2.0 23.4 ± 4.5 99.8
Calcibon 16.1 ± 5.9 53.7 5.8 ± 3.8 21.2 ± 0.5 99.8
Chronos 25.6 ± 3.3 85.3a,b 0.5 ± 0.3 22.0 ± 5.5 99.1
Norian 10.8 ± 3.8 36.0 6.4 ± 0.0 16.9 ± 8.4 99.8
Granules
Allogran 15.2 ± 9.6 50.7 0.0 16.5 ± 10.0 99.8
Bicalphos 13.4 ± 8.2 44.7 0.0 15.3 ± 9.9 99.8
Biosorb 9.6 ± 2.7 32.0 0.0 11.5 ± 6.0 99.8
Bonesave 9.1 ± 5.5 30.3 0.0 10.0 ± 4.6 99.7
Cerasorb 10.8 ± 7.1 36.0 0.0 11.1 ± 7.1 99.8
Vitoss 18.6 ± 8.3 62.0 0.0 18.6 ± 10.1 99.4